MedTrace Logo

The Effects of Omega-3 Fatty Acids on Metabolic Syndrome

NCT00350194 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2012-03-02

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of omega-3 fatty acids in the form of fish oil supplementation (approximately 2 grams per day) on the carotid intima-media (CIMT)progression (primary objective) and 2)(Secondary objective) lipid markers such as LDL, apo-B, and LDL buoyancy, on inflammatory burden as measured by CRP, on oxidative stress as measured by urinary isoprostanes, urine microalbumin/creatinine, and serum adiponectin a fat derived hormone in subjects with metabolic syndrome.

Conditions

  • Metabolic Syndrome X

Interventions

DIETARY_SUPPLEMENT

Omega-3 fatty acids

Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • National Institutes of Health (NIH)

    collaborator NIH

  • Northwest Lipid Research Clinic

    collaborator UNKNOWN

  • University of Washington

    lead OTHER

Principal Investigators

  • Pathmaja Paramsothy, MD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2011-10-31
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00350194 on ClinicalTrials.gov